Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Pentheroudakis, George ^a,b   Pavlidis, Nicholas ^a,b   Fountzilas, George ^c   Krikelis, Dimitrios ^c   Goussia, Anna ^a,b   Stoyianni, Aikaterini ^a,b   Sanden, Mats ^d   St Cyr, Brianna ^d   Yerushalmi, Noga ^e   Benjamin, Hila ^e   Meiri, Eti ^e   Chajut, Ayelet ^e   Rosenwald, Shai ^e   Aharonov, Ranit ^e   Spector, Yael ^e  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d Rosetta Genomics Inc   (United States)

^e ROSETTA GENOMICS LTD   (Israel)

Author keywords

Carcinoma of Unknown Primary (CUP); MicroRNA; Molecular diagnostics; Tumor of origin

Indexed keywords

MICRORNA;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; COHORT ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS;

AGED; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICRORNAS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS, UNKNOWN PRIMARY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84878722022     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-57     Document Type: Article

References (32)

1. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 2007, 356:185-187. 10.1056/NEJMe068263, 17215538.
2. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51. 10.1056/NEJMra043186, 17611206.
3. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676. 10.1056/NEJMoa072113, 18160686.
4. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144. 10.1056/NEJMoa050736, 16014883.
5. Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 2008, 9:596-599. 10.1016/S1470-2045(08)70151-7, 18510991.
6. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995, 13:2094-2103.
7. Anderson GG, Weiss LM. Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. Appl Immunohistochem Mol Morphol 2010, 18:3-8. 10.1097/PAI.0b013e3181a75e6d, 19550296.
8. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005, 11:3766-3772. 10.1158/1078-0432.CCR-04-2236, 15897574.
9. Oien KA, Dennis JL. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. Ann Oncol 2012, 23(Suppl 10):x271-x277. 10.1093/annonc/mds357, 22987975.
10. Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008, 26:4435-4441. 10.1200/JCO.2007.14.6969, 18802156.
11. Ma XJ, Patel R, Wang X, Salunga R, Murage J, Desai R, Tuggle JT, Wang W, Chu S, Stecker K, et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006, 130:465-473.
12. Monzon FA, Lyons-Weiler M, Buturovic LJ, Rigl CT, Henner WD, Sciulli C, Dumur CI, Medeiros F, Anderson GG. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 2009, 27:2503-2508. 10.1200/JCO.2008.17.9762, 19332734.
13. Meiri E, Mueller WC, Rosenwald S, Zepeniuk M, Klinke E, Edmonston TB, Werner M, Lass U, Barshack I, Feinmesser M, et al. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist 2012, 17:801-812. 10.1634/theoncologist.2011-0466, 3380879, 22618571.
14. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009, 27:2030-2037. 10.1200/JCO.2008.19.4134, 19273703.
15. Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, Schlosberg A, Kuker H, Sion-Vardy N, Tobar A, Kharenko O, et al. MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol 2009, 19:375-383. 10.1111/j.1750-3639.2008.00184.x, 2728890, 18624795.
16. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008, 93:1600-1608. 10.1210/jc.2007-2696, 2386678, 18270258.
17. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008, 26:462-469. 10.1038/nbt1392, 18362881.
18. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3:e3148. 10.1371/journal.pone.0003148, 2519789, 18773077.
19. Li J, Smyth P, Flavin R, Cahill S, Denning K, Aherne S, Guenther SM, O'Leary JJ, Sheils O. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 2007, 7:36. 10.1186/1472-6750-7-36, 1914054, 17603869.
20. Liu A, Tetzlaff MT, Vanbelle P, Elder D, Feldman M, Tobias JW, Sepulveda AR, Xu X. MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int J Clin Exp Pathol 2009, 2:519-527. 2713447, 19636399.
21. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838. 10.1038/nature03702, 15944708.
22. Erlander MG, Ma XJ, Kesty NC, Bao L, Salunga R, Schnabel CA. Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn 2011, 13:493-503. 10.1016/j.jmoldx.2011.04.004, 3157614, 21708287.
23. Rosenwald S, Gilad S, Benjamin S, Lebanony D, Dromi N, Faerman A, Benjamin H, Tamir R, Ezagouri M, Goren E, et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol 2010, 23:814-823. 10.1038/modpathol.2010.57, 20348879.
24. Bridgewater J, van Laar R, Floore A, Van TVL. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer 2008, 98:1425-1430. 10.1038/sj.bjc.6604315, 2361712, 18414470.
25. Greco FA, Lennington WJ, Spigel DR, Hainsworth JD. Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology. J Natl Cancer Inst 2013, 105(11):782-790. 10.1093/jnci/djt099, 23641043.
26. Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma XJ, Hainsworth JD. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 2010, 15:500-506. 10.1634/theoncologist.2009-0328, 3227979, 20427384.
27. Mueller WC, Spector Y, Edmonston TB, St Cyr B, Jaeger D, Lass U, Aharonov R, Rosenwald S, Chajut A. Accurate classification of metastatic brain tumors using a novel microRNA-based test. Oncologist 2011, 16:165-174. 10.1634/theoncologist.2010-0305, 3228095, 21273512.
28. Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, et al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 2011, 17:4063-4070. 10.1158/1078-0432.CCR-10-2599, 21531815.
29. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008, 26:4442-4448. 10.1200/JCO.2007.14.4378, 18802157.
30. Gilad S, Lithwick-Yanai G, Barshack I, Benjamin S, Krivitsky I, Edmonston TB, Bibbo M, Thurm C, Horowitz L, Huang Y, et al. Classification of the four main types of lung cancer using a microRNA-based diagnostic assay. J Mol Diagn 2012, 14:510-517. 10.1016/j.jmoldx.2012.03.004, 22749746.
31. Greco FA, Oien K, Erlander M, Osborne R, Varadhachary G, Bridgewater J, Cohen D, Wasan H. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol 2012, 23:298-304. 10.1093/annonc/mdr306, 21709138.
32. Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 2012, 31:217-223.